Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

135 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer.
Piccart MJ, Di Leo A, Beauduin M, Vindevoghel A, Michel J, Focan C, Tagnon A, Ries F, Gobert P, Finet C, Closon-Dejardin MT, Dufrane JP, Kerger J, Liebens F, Beauvois S, Bartholomeus S, Dolci S, Lobelle JP, Paesmans M, Nogaret JM. Piccart MJ, et al. Among authors: ries f. J Clin Oncol. 2001 Jun 15;19(12):3103-10. doi: 10.1200/JCO.2001.19.12.3103. J Clin Oncol. 2001. PMID: 11408507 Clinical Trial.
Long-term benefit of high-dose epirubicin in adjuvant chemotherapy for node-positive breast cancer: 15-year efficacy results of the Belgian multicentre study.
de Azambuja E, Paesmans M, Beauduin M, Vindevoghel A, Cornez N, Finet C, Ries F, Closon-Dejardin MT, Kerger J, Gobert P, Focan C, Tagnon A, Dolci S, Nogaret JM, di Leo A, Piccart-Gebhart MJ. de Azambuja E, et al. Among authors: ries f. J Clin Oncol. 2009 Feb 10;27(5):720-5. doi: 10.1200/JCO.2008.17.2155. Epub 2008 Dec 22. J Clin Oncol. 2009. PMID: 19103732 Clinical Trial.
HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide.
Di Leo A, Larsimont D, Gancberg D, Jarvinen T, Beauduin M, Vindevoghel A, Michel J, Focan CH, Ries F, Gobert PH, Closon-Dejardin MT, Dolci S, Rouas G, Paesmans M, Lobelle JP, Isola J, Piccart MJ. Di Leo A, et al. Among authors: ries f. Ann Oncol. 2001 Aug;12(8):1081-9. doi: 10.1023/a:1011669223035. Ann Oncol. 2001. PMID: 11583189 Free article. Clinical Trial.
[Apoptosis and cancer].
Duhem C, Ries F, Dicato M. Duhem C, et al. Among authors: ries f. Bull Soc Sci Med Grand Duche Luxemb. 1994;131(1):39-48. Bull Soc Sci Med Grand Duche Luxemb. 1994. PMID: 8050118 Review. French. No abstract available.
[Resistance to chemotherapy: current therapeutic approach].
Ries F, Pauly M, Poeckes L, Duhem C, Dicato M. Ries F, et al. Bull Soc Sci Med Grand Duche Luxemb. 1995;132(3):19-26. Bull Soc Sci Med Grand Duche Luxemb. 1995. PMID: 8665621 Review. French. No abstract available.
135 results